Search for risk markers of development of pathology. Hepatobiliary system based on genetic polymorphism of xenobiotic detoxification system genes study
Abstract
The aim of this study was to compare the frequencies of genotypes and alleles of polymorphic variants of the CYP2E1 and GSTA1 genes in patients with hepatobiliary system pathology who were examined at the Ufa Scientific Research Institute of Occupational Medicine and Human Ecology and healthy individuals living in the Republic of Bashkortostan who have no hepatobiliary system pathology.
Materials and methods: 81 patients with pathology of the hepatobiliary system and 502 practically healthy individuals living in the Republic of Bashkortostan were examined. The material for molecular genetic analysis was DNA samples isolated from the peripheral venous blood of the examined individuals by phenol-chloroform extraction. The study of polymorphic loci of the CYP2E1 and GSTA1 genes was carried out by the method of polymerase chain reaction of DNA synthesis. Mathematical processing of the results of the study was carried out using the statistical program Statistics.
Results. A comparative analysis revealed statistically significant differences between the group of patients with ASD and healthy individuals in the frequency distribution of the genotypes of the polymorphic locus rs3957357 of the GSTA1 gene. The AA genotype was more common in patients with ASD with a frequency of 16.05%, compared with the control group –8.37% (χ2 = 3.96; p = 0.047). Conclusion As a result of the study, it was shown that the AA genotype (OR = 2.09; 95% CI 1.07 - 4.10) of the polymorphic locus rs3957357 of the GSTA1 gene is a marker of the risk of pathology of the hepatobiliary system.
Downloads
References
Valeeva E. T., Bakirov A. B., & Karimova L. K. (2009). Features of occupational diseases and intoxications in workers of modern petrochemical and chemical industries. Bulletin of the VSSC SB RAMS, 1 (65), 59-63.
Tang K., Li Y., & Zhang Z. (2010). The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies. BMC Cancer, 10, 575-577.
Limborskaya S.A., Verbenko D.A., & Khrunin A.V. (2011). Ethnic genomics: analysis of genomic polymorphism of populations of the Arkhangelsk region. Moscow University Physics Bulletin. Series 23: Anthropology, 3, 100-119.
Abdel-Rahman S.Z., Salama S.A., & Au W.W. (2010). Role of polymorphic CYP2E1 and CYP2D6 genes in NNK-induced chromosome aberrations in cultured human lymphocytes. Pharmacogenetics, 10(3), 239–249.
Podprasart V., Satayavivad J., & Riengrojpitak S. (2007). No direct hepatotoxic potential following a multiple-low dose paraquat exposure in rat as related to its bioaccumulation. Toxicol Lett, 170(3), 193-202.
Sun F., Chen Y., & Xiang Y. (2008). Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis, 12(9), 994-1002.
Kravchenko N.O., Vinogradova S.V. (2004). Significance of genetic factors in development and progressive liver steatosis. Suchas gastroenterology, 4, 107-114.
Coles B. F., Morel F., & Rauch C. (2001). Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics, 11(8), 663-669.
Deng Q., He B., & Pan Y. (2015). Polymorphisms of GSTA1 contribute to elevated cancer risk: evidence from 15 studies. J BUON, 20(1), 287-295.
Komiya Y., Tsukino H., & Nakao H. (2005). Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population. J Cancer Res Clin Oncol, 131(4), 238-242.
Ning B., Wang C., & Morel F. (2014). Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics, 14(1), 35-44.
Vodicka P., Stetina R., & Koskinen M. (2012). New aspects in the biomonitoring of occupational exposure to styrene. Int. Arch. Occup. Environ. Health, 75, 75–85.
.gif)
